Use of betulinic acid in preparing glycosidase inhibitor medicine

Abstract

The invention provides the application of betulinic acid and salts thereof suitable for medical purpose in the preparation of a drug of a glycosidase inhibitor. The compound of the invention is the compound of lupeol type pentacyclic triterpene acid obtained by separating lagerstroemia plants. Pharmacological tests prove that the compound has obvious effect in inhibiting Alpha-glucosidase, the inhibitory activity of which exceeds acarbose 100% for initial therapy. Therefore, drug compositions made from the compound or the salts thereof suitable for medical purpose and drug excipients or carriers allowable for preparation can be applied to the preparation of drugs for preventing or treating Type II Diabetes, namely, noninsulin-dependent diabetes mellitus. The constitutional formula shown in formula (1) of the invention is shown as above.

Description

technical field

[0001] The present invention relates to the field of natural medicinal chemistry, in particular, the present invention relates to the use of betulinic acid, a pentacyclic triterpene acid compound isolated from Lagerstroemia genus, for the preparation of glycosidase inhibitor drugs. The compound has the biological activity of potently inhibiting α-glucosidase, so the compound or its pharmaceutically acceptable salt, and the pharmaceutical composition prepared with the pharmaceutical excipient or carrier allowed by the formulation can be expected to be used as a glucosidase inhibitor The medicine is especially used for preventing and treating type II diabetes, that is, non-insulin-dependent diabetes mellitus. Background technique

[0002] With the advancement of science and technology and the improvement of living standards, the incidence of diabetes is increasing worldwide. According to statistics, diabetes occurs in about 3% of people, and the total number o...

Images